{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:19:24Z","timestamp":1787847564088,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease characterized by increased pulmonary vascular resistance, right ventricular failure, and systemic inflammation. Novel biomarkers reflecting disease severity and prognosis are needed for improved risk stratification in PAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To evaluate the relationship between neutrophil percentage-to-albumin ratio (NPAR) and disease severity in patients with Group 1 pulmonary arterial hypertension, and to determine its prognostic value as an inflammatory biomarker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective cohort study conducted on patients with Group 1 PAH. The study included 50 PAH patients (30 New York Heart Association [NYHA] class I-II, 20 class III-IV) and 25 healthy controls without cardiovascular or inflammatory disease for biomarker analysis. Clinical characteristics, laboratory parameters, and echocardiographic data were collected. NPAR was calculated, and its correlation with disease severity and other inflammatory markers was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      High-sensitivity C-reactive protein (hs-CRP) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02), N-Terminal Pro-Brain Natri\u00fcretic Peptid (NT-proBNP) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03), NPAR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01), white blood cell (WBC) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03), neutrophil (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02), and albumin (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02) levels were significantly elevated in PAH patients compared to healthy controls. There was a strong correlation between NPAR and established markers of disease severity, specifically systolic pulmonary artery pressure (sPAP), right atrial (RA) area, NT-proBNP, and 6-min walk distance. According to the receiver operating characteristic (ROC) analysis, an NPAR threshold exceeding 18.2 proved to be a significant predictor for PAH (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05) and yielded a sensitivity of 80% and a specificity of 71%, with an area under the curve (AUC) of 0.966 (95% confidence interval (CI): 0.95\u20130.98). NPAR emerged as an independent predictor of PAH and high-risk PAH in multivariate analysis [1.029 (1.018\u20131.039),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The study demonstrates that NPAR is a promising biomarker for assessing disease severity and predicting prognosis in PAH. Elevated NPAR levels may reflect systemic inflammation and contribute to the pathogenesis of PAH. Further research is needed to explore the potential therapeutic implications of targeting inflammation in PAH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_816_25","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:00:08Z","timestamp":1780016408000},"page":"559-566","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Neutrophil Percentage-to-Albumin Ratio as a Novel Biomarker in Patients with Group 1 Pulmonary Arterial Hypertension"],"prefix":"10.4103","volume":"29","author":[{"given":"\u0130","family":"Akta\u015f","sequence":"first","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Malatya Turgut \u00d6zal University, Malatya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Ya\u015far","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Malatya Training and Research Hospital, Malatya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"R1-20260529","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1513\/pats.200510-112JH","article-title":"Pulmonary arterial hypertension","volume":"3","author":"Rubin","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"R2-20260529","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R3-20260529","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/303059","article-title":"Familial primary pulmonary hypertension (gene PPH 1) is caused by mutations in the bone morphogenetic protein receptor-II gene","volume":"67","author":"Deng","year":"2000","journal-title":"Am J Hum Genet"},{"key":"R4-20260529","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1378\/chest.12-1246","article-title":"Biomarkers in pulmonary hypertension: What do we know?","volume":"144","author":"Foris","year":"2013","journal-title":"Chest"},{"key":"R5-20260529","first-page":"275","article-title":"Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension","volume":"144","author":"Tuder","year":"1994","journal-title":"Am J Pathol"},{"key":"R6-20260529","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jacc.2008.12.038","article-title":"C-reactive protein: A new predictor of adverse outcome in pulmonary arterial hypertension","volume":"53","author":"Quarck","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R7-20260529","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200108023450502","article-title":"Mutations in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred","volume":"345","author":"Newman","year":"2001","journal-title":"N Engl J Med"},{"key":"R8-20260529","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","article-title":"Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension","volume":"151","author":"Humbert","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"R9-20260529","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.3390\/nu15081892","article-title":"Predictive role of neutrophil-percentage-to-albumin ratio (NPAR) in nonalcoholic fatty liver disease and advanced liver fibrosis in nondiabetic US adults: Evidence from NHANES 2017\u20132018","volume":"15","author":"Liu","year":"2023","journal-title":"Nutrients"},{"key":"R10-20260529","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IJGM.S323114","article-title":"Neutrophil albumin ratio is associated with all-cause mortality in stroke patients: A retrospective database study","volume":"15","author":"Chen","year":"2022","journal-title":"Int J Gen Med"},{"key":"R11-20260529","first-page":"1","article-title":"Association between neutrophil percentage-to-albumin ratio and all-cause mortality in critically ill patients with coronary artery disease","volume":"8137576","author":"Sun","year":"2020","journal-title":"Biomed Res Int"},{"key":"R12-20260529","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"R13-20260529","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"R14-20260529","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: Guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R15-20260529","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","article-title":"Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension","volume":"115","author":"Rabinovitch","year":"2014","journal-title":"Circ Res"},{"key":"R16-20260529","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1164\/ajrccm.165.4.2012112","article-title":"Chemokine RANTES in severe pulmonary arterial hypertension","volume":"165","author":"Dorfm\u00fcller","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R17-20260529","doi-asserted-by":"crossref","first-page":"L1013","DOI":"10.1152\/ajplung.00217.2009","article-title":"Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure","volume":"297","author":"Stenmark","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R18-20260529","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1017\/S0950268820000771","article-title":"Increased neutrophil percentage-to-albumin ratio is associated with all cause mortality in patients with severe sepsis or septic shock","volume":"148","author":"Gong","year":"2020","journal-title":"Epidemiol Infect"},{"key":"R19-20260529","doi-asserted-by":"crossref","first-page":"5687672","DOI":"10.1155\/2020\/5687672","article-title":"The neutrophil percentage-to-albumin ratio is associated with all-cause mortality in critically ill patients with acute kidney injury","author":"Wang","year":"2020","journal-title":"Biomed Res Int"},{"key":"R20-20260529","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.12659\/MSM.917987","article-title":"The neutrophil percentage to albumin ratio as a new predictor of in-hospital mortality in patients with ST-segment elevation myocardial infarction","volume":"25","author":"Cui","year":"2019","journal-title":"Med Sci Monit"},{"key":"R21-20260529","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12890-017-0407-5","article-title":"Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension","volume":"17","author":"Harbaum","year":"2017","journal-title":"BMC Pulm. Med"},{"key":"R22-20260529","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12882-025-04027-0","article-title":"Predictive value of neutrophil percentage-to-albumin ratio for mortality in maintenance hemodialysis patients: A multicenter cohort study","volume":"26","author":"Zhu","year":"2025","journal-title":"BMC Nephrol"},{"key":"R23-20260529","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12890-025-03757-z","article-title":"The clinical usefulness of neutrophil percentage\/albumin ratio in predicting the one-month mortality in chronic obstructive pulmonary disease patients hospitalized with community-acquired pneumonia","volume":"25","author":"G\u00fcl","year":"2025","journal-title":"BMC Pulm Med"},{"key":"R24-20260529","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00246-013-0715-3","article-title":"Inflammatory markers are elevated are in Eisenmenger syndrome","volume":"34","author":"Ramakrishnan","year":"2013","journal-title":"Pediatr. Cardiol"},{"key":"R25-20260529","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1378\/chest.11-0793","article-title":"Inflammation in pulmonary arterial hypertension","volume":"141","author":"Price","year":"2012","journal-title":"Chest"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_816_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:21:55Z","timestamp":1787844115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_816_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_816_25","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-11-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}